Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 8/20 | 0.45 |
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | RAF1 | P04049 | 6/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31232515 | 0.93 | BRAF (0.45) | KIF11FAAHBRAFRAF1AKR1C3 | |
| SCHEMBL14378616 | 0.85 | FFAR1 (0.52) | FAAHAKR1C3AKR1C2 | |
| SCHEMBL31232630 | 0.85 | BRAF (0.43) | FAAHBRAFRAF1AKR1C3AKR1C2 | |
| SCHEMBL25026111 | 0.82 | NOTUM (0.43) | NOTUM | |
| SCHEMBL30934635 | 0.82 | NOTUM (0.43) | NOTUM | |
| SCHEMBL11976208 | 0.82 | ADRB3 (0.52) | FAAH | |
| SCHEMBL31232502 | 0.82 | FAAH (0.50) | FAAH | |
| SCHEMBL31232685 | 0.81 | APOB (0.41) | FAAHBRAFRAF1 | |
| SCHEMBL31232478 | 0.80 | FAAH (0.49) | FAAH | |
| SCHEMBL31232712 | 0.80 | FAAH (0.44) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | KIF11 2439/4885FAAH 3371/4885BRAF 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.